Optimizing Anticancer Therapy in Prostate Cancer Guideline

ASCO Guidelines
02/04/2018 17 min Episodio 3
Optimizing Anticancer Therapy in Prostate Cancer Guideline

Listen "Optimizing Anticancer Therapy in Prostate Cancer Guideline"

Descargar episodio Ver en sitio original

Episode Synopsis

An interview with Dr. Michael J. Morris from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine on the ASCO clinical practice guideline which addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Read the full guideline at www.asco.org/genitourinary-cancer-guidelines 

More episodes of the podcast ASCO Guidelines

Treatment of Multiple Myeloma: ASCO-OH (CCO) Living Guideline 06/01/2026
Management of Cancer During Pregnancy Guideline 11/12/2025
Management of Antineoplastic Extravasation: ONS-ASCO Guideline 18/09/2025
Postmastectomy Radiation Therapy: ASTRO-ASCO-SSO Guideline 16/09/2025
Geriatric Assessment Global Guideline 27/08/2025
Oncology Medical Homes: ASCO-COA Standards Update 21/07/2025
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2025.1 Part 2 17/07/2025
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2025.1 Part 1 17/07/2025
Medically Integrated Dispensing Pharmacy: ASCO-NCODA Standards Update 27/05/2025
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Guideline 09/05/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA